ClinicalTrials.gg
CompletedNCT06107036Updated Nov 28, 2025Results posted

A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities

A Phase 1 interventional study of BI 1015550 and Moxifloxacin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main objective of this trial is to evaluate the effects of a single therapeutic and a single supra-therapeutic dose of BI 1015550 following oral administration on cardiac safety parameters in healthy male and female volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs - blood pressure (BP) and pulse rate (PR), 12-lead (ECG), and clinical laboratory tests without any abnormalities
  2. Age of 18 to 50 years (inclusive)
  3. of 18.5 to 32 kg/m\^2 (inclusive)
  4. Signed and dated written in accordance with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  5. Either male subjects, or female subjects meet the following criteria requiring highly effective from at least 30 days before the first administration of trial medication until 37 days after the last administration of the study drug:

    • Male participants must use condom plus their partner, if identified as a women of (WOCBP), must use an oral contraceptive or highly effective contraception
    • Female participants must be using highly effective contraception and in addition their male partner must use a condom if they are using an oral contraceptive

Exclusion criteria

Exclusion Criteria:

  1. Any finding in the medical examination (including BP, Heart rate (HR) or ) deviating from normal and assessed as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or heart rate outside the range of 50 to 90 beats per minute (bpm)
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, in particular, hepatic parameters (, aspartate transaminase, total ) or renal parameters (creatinine) exceeding the
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders assessed as clinically relevant by the investigator
  6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders including but not limited to depression and suicidal behaviour
  8. History of clinically relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Sequence 1: H/M/P2/L/P1

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 2: H/P1/L/P2/M

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 3: H/L/P2/M/P1

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 4: M/H/L/P1/P2

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 5: M/P1/L/H/P2

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 6: M/P2/H/L/P1

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 7: P1/M/H/P2/L

    Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 8: P1/P2/H/M/L

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 9: P1/L/M/H/P2

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 10: P2/H/P1/M/L

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 11: P2/P1/M/L/H

    Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 12: P2/L/M/P1/H

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 13: L/H/P1/P2/M

    Participants in this study received five treatments in the order described below. Each treatment was administered orally with 240 mL of water following an overnight fast of at least 10 hours. A washout period of at least 7 days separated each treatment. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 14: L/M/P2/P1/H

    Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 15: L/P2/P1/H/M

    Participants in this study received five treatments ordered as described below. Each treatment was administered orally with 240 mL of water after an overnight fast of at least 10 hours. Each treatment was separated by a wash-out period of at least 7 days. L (low-dose nerandomilast): Participants received film-coated tablets containing a low dose of nerandomilast. P2 (Placebo 2): Participants received placebo tablets designed to match the high-dose nerandomilast group. P1 (Placebo 1): Participants received placebo tablets designed to match the low-dose nerandomilast group. H (high-dose nerandomilast): Participants received film-coated tablets containing a high dose of nerandomilast. M (high-dose moxifloxacin - Positive Control): Participants received film-coated tablets containing a high dose of moxifloxacin as a positive control.

    Drug: BI 1015550 · Drug: Moxifloxacin · Drug: Placebo

Interventions

  • BI 1015550 administered as low (L), and high (H), dose. Oral tablet.

    Also known as: Nerandomilast, JASCAYD®

  • Moxifloxacin was used as positive control, given as a high dose. Oral tablet.

    Also known as: Avelox®

  • DrugPlacebo

    Placebo was administered as low (P1), matching the low-dose nerandomilast group, and as high (P2), matching the high-dose neradnomilast group. Oral tablet.

06

What researchers measure

Primary outcomes

  1. The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration

    QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for each dose of nerandomilast (e.g., low dose, high dose) with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.

    Time frame: MMRM included measurements at these time points [hours:minutes] post-drug: 0:20, 1:00, 1:30, 2:00, 2:30, 3:00, 3:30, 4:00, 4:30, 5:00, 6:00, 8:00, 12:00, and 24:00. MMRM values at 12:00 (low dose) and 4:30 (high dose) are shown in the table below.

Secondary outcomes

  1. The Maximum Mean Difference Between Moxifloxacin and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration.

    QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for moxifloxacin with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.

    Time frame: MMRM included measurements at these time points [hours:minutes] post-drug: 0:20, 1:00, 1:30, 2:00, 2:30, 3:00, 3:30, 4:00, 4:30, 5:00, 6:00, 8:00, 12:00, and 24:00. MMRM values at 3:30 (high dose moxifloxacin) are shown in the table below.

07

Results

Posted Nov 28, 2025

Participant flow

This randomized, placebo-controlled, double-blind (moxifloxacin: open-label), crossover study had 5 treatment periods separated by ≥7-day washouts. Treatments included a low dose nerandomilast \[L\], a high dose nerandomilast \[H\], a high dose moxifloxacin (positive control) \[M\]), and placebo \[P1, P2\]. The study assessed nerandomilast's effect on cardiac safety (QT/QTc interval) in healthy female and male participants across 15 sequences, each with 3 participants.

Treated in period 1
Participant flow — Treated in period 1
MilestoneSequence 1: H/M/P2/L/P1Sequence 2: H/P1/L/P2/MSequence 3: H/L/P2/M/P1Sequence 4: M/H/L/P1/P2Sequence 5: M/P1/L/H/P2Sequence 6: M/P2/H/L/P1Sequence 7: P1/M/H/P2/LSequence 8: P1/P2/H/M/LSequence 9: P1/L/M/H/P2Sequence 10: P2/H/P1/M/LSequence 11: P2/P1/M/L/HSequence 12: P2/L/M/P1/HSequence 13: L/H/P1/P2/MSequence 14: L/M/P2/P1/HSequence 15: L/P2/P1/H/M
Started333333333334333
Completed333333333334333
Not completed000000000000000
Treated in period 2
Participant flow — Treated in period 2
MilestoneSequence 1: H/M/P2/L/P1Sequence 2: H/P1/L/P2/MSequence 3: H/L/P2/M/P1Sequence 4: M/H/L/P1/P2Sequence 5: M/P1/L/H/P2Sequence 6: M/P2/H/L/P1Sequence 7: P1/M/H/P2/LSequence 8: P1/P2/H/M/LSequence 9: P1/L/M/H/P2Sequence 10: P2/H/P1/M/LSequence 11: P2/P1/M/L/HSequence 12: P2/L/M/P1/HSequence 13: L/H/P1/P2/MSequence 14: L/M/P2/P1/HSequence 15: L/P2/P1/H/M
Started333333333333333
Completed333333333333333
Not completed000000000000000
Treated in period 3
Participant flow — Treated in period 3
MilestoneSequence 1: H/M/P2/L/P1Sequence 2: H/P1/L/P2/MSequence 3: H/L/P2/M/P1Sequence 4: M/H/L/P1/P2Sequence 5: M/P1/L/H/P2Sequence 6: M/P2/H/L/P1Sequence 7: P1/M/H/P2/LSequence 8: P1/P2/H/M/LSequence 9: P1/L/M/H/P2Sequence 10: P2/H/P1/M/LSequence 11: P2/P1/M/L/HSequence 12: P2/L/M/P1/HSequence 13: L/H/P1/P2/MSequence 14: L/M/P2/P1/HSequence 15: L/P2/P1/H/M
Started333333333333333
Completed333333333333333
Not completed000000000000000
Treated in period 4
Participant flow — Treated in period 4
MilestoneSequence 1: H/M/P2/L/P1Sequence 2: H/P1/L/P2/MSequence 3: H/L/P2/M/P1Sequence 4: M/H/L/P1/P2Sequence 5: M/P1/L/H/P2Sequence 6: M/P2/H/L/P1Sequence 7: P1/M/H/P2/LSequence 8: P1/P2/H/M/LSequence 9: P1/L/M/H/P2Sequence 10: P2/H/P1/M/LSequence 11: P2/P1/M/L/HSequence 12: P2/L/M/P1/HSequence 13: L/H/P1/P2/MSequence 14: L/M/P2/P1/HSequence 15: L/P2/P1/H/M
Started333333333333333
Completed333333333333333
Not completed000000000000000
Treated in period 5
Participant flow — Treated in period 5
MilestoneSequence 1: H/M/P2/L/P1Sequence 2: H/P1/L/P2/MSequence 3: H/L/P2/M/P1Sequence 4: M/H/L/P1/P2Sequence 5: M/P1/L/H/P2Sequence 6: M/P2/H/L/P1Sequence 7: P1/M/H/P2/LSequence 8: P1/P2/H/M/LSequence 9: P1/L/M/H/P2Sequence 10: P2/H/P1/M/LSequence 11: P2/P1/M/L/HSequence 12: P2/L/M/P1/HSequence 13: L/H/P1/P2/MSequence 14: L/M/P2/P1/HSequence 15: L/P2/P1/H/M
Started333333333333333
Completed333333333333333
Not completed000000000000000

Outcome measures

PrimaryThe Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration

QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for each dose of nerandomilast (e.g., low dose, high dose) with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.

Time frame:
MMRM included measurements at these time points [hours:minutes] post-drug: 0:20, 1:00, 1:30, 2:00, 2:30, 3:00, 3:30, 4:00, 4:30, 5:00, 6:00, 8:00, 12:00, and 24:00. MMRM values at 12:00 (low dose) and 4:30 (high dose) are shown in the table below.
Reported as:
Least squares mean · Milliseconds
The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration
MillisecondsLow-dose nerandomilastHigh-dose nerandomilast
The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration3.0 (0.7 to 5.4)3.2 (1.2 to 5.2)
SecondaryThe Maximum Mean Difference Between Moxifloxacin and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration.

QT interval corrected for heart rate (using the method of Fridericia, QTcF) changes from baseline, measured between 20 minutes and 24 hours after drug administration, were analyzed using a linear Mixed Model for Repeated Measures (MMRM). Pairwise comparison was used to compare the QTcF changes for moxifloxacin with the placebo at every time point. Mean treatment differences in the QTcF changes from baseline at each time point were estimated by the differences in the corresponding least-squares means. Two-sided 90% confidence intervals based on the t-distribution were computed for each time point. The MMRM was adjusted for the discrete fixed effects treatment, period, time, the continuous fixed effects period- and participant-baseline, the fixed effect-by-time terms, participant as random effect and time within period as a repeated effect per participant. The covariance structure for the repeated effect time was unstructured.

Time frame:
MMRM included measurements at these time points [hours:minutes] post-drug: 0:20, 1:00, 1:30, 2:00, 2:30, 3:00, 3:30, 4:00, 4:30, 5:00, 6:00, 8:00, 12:00, and 24:00. MMRM values at 3:30 (high dose moxifloxacin) are shown in the table below.
Reported as:
Least squares mean · Milliseconds
The Maximum Mean Difference Between Moxifloxacin and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration.
MillisecondsHigh-dose moxifloxacin - Positive Control
The Maximum Mean Difference Between Moxifloxacin and Placebo in QTcF Changes From Baseline Between 20 Min to 24 Hours After Drug Administration.14.2 (12.4 to 16.1)

Adverse events

Collected over Adverse Events: up to 7 days following drug administration for placebo 1 and 2, low-dose nerandomilast, and high-dose nerandomilast, and for up to 4 days following administration of high-dose moxifloxacin. All-Cause Mortality: from the first drug administration on Day 1 until the end of the trial, up to a total of 44 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo 10/45 (0%)0/45 (0%)0/45 (0%)
Placebo 20/46 (0%)0/46 (0%)4/46 (8.7%)
Low-dose nerandomilast0/45 (0%)0/45 (0%)4/45 (8.9%)
High-dose nerandomilast0/45 (0%)0/45 (0%)3/45 (6.7%)
High-dose moxifloxacin - Positive Control0/45 (0%)0/45 (0%)3/45 (6.7%)
Most frequent other events
Most frequent other events
EventPlacebo 1Placebo 2Low-dose nerandomilastHigh-dose nerandomilastHigh-dose moxifloxacin - Positive Control
HeadacheNervous system disorders0/454/464/453/453/45

Baseline characteristics

Treated set (TS): The treated set includes all subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)All Participants
Mean36.9 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female21
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino3
Not Hispanic or Latino43
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White44
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Jul 2024, 4 months.

Results were first posted in Nov 2025, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartActual
Mar 6, 2024
Primary completionActual
Jul 25, 2024
CompletionActual
Jul 25, 2024
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06107036
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Mar 6, 2024
Primary completion
Jul 25, 2024
Completion
Jul 25, 2024
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion